Production of extended release mini-tablets using directly compressible grades of HPMC

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1690-1697

  Mohamed, Faiezah A A ^a   Roberts, Matthew ^a   Seton, Linda ^a   Ford, James L ^a   Levina, Marina ^b   Rajabi Siahboomi, Ali R ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b Colorcon Ltd ^*  (United Kingdom)

Author keywords

DC; Extended release; Flowability; HPMC; Mini tablets; Production speed

Indexed keywords

AEROSIL; HYDROCORTISONE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MAGNESIUM STEARATE; TABLETTOSE 80; THEOPHYLLINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULATION; DRUG SOLUBILITY; FLOW; PARTICLE SIZE; SIMULATION; SUSTAINED DRUG RELEASE; TABLET COMPRESSION; TABLET MANUFACTURE; TENSILE STRENGTH;

ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; EXCIPIENTS; HYDROCORTISONE; KINETICS; MECHANICAL PHENOMENA; METHYLCELLULOSE; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; QUALITY CONTROL; SOLUBILITY; SURFACE PROPERTIES; TABLETS; TENSILE STRENGTH; THEOPHYLLINE;

EID: 84885630266     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.730524     Document Type: Article

References (36)

1. Maderuelo C, Zarzuelo A, Lanao JM. (2011). Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release, 154:2-19
2. Ghimire M, Hodges LA, Band J, OMahony B, McInnes FJ, Mullen AB et al. (2010). In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. J Control Release, 147:70-75
3. Hardy IJ, Cook WG, Melia CD. (2006). Compression and compaction properties of plasticised high molecular weight hydroxypropylmethylcellulose (HPMC) as a hydrophilic matrix carrier. Int J Pharm, 311:26-32
4. Alderborn G. (2002). Tablet and compaction. In: Aultons Pharmaceutics: The science of dosage from design. 2nd edition. Leicester: Churchill Livingstone, 402-423
5. Gohel MC, Jogani PD. (2005). A review of co-processed directly compressible excipients. J Pharm Pharm Sci, 8:76-93
6. Villanova JC, Ayres E, Oréfice RL. (2011). Design of prolonged release tablets using new solid acrylic excipients for direct compression. Eur J Pharm Biopharm, 79:664-673
7. Wells J. (2002). Pharmaceuticl preformulations: The physiochemical properties of drug substance. In: Aultons Pharmaceutics: The science of dosage from design. 2nd edition. Leicester: Churchill Livingstone, 113-138
8. Flemming J, Mielck JB. (1995). Requirements for the production of microtablets: Suitability of direct-compression excipients estimated from powder characteristics and flow rates. Drug Dev Ind Pharm, 21. 2239-2251
9. Shah R, Tawakkul M, Khan M. (2008). Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech, 9: 250-258
10. Stoltenberg I, Breitkreutz J. (2011). Orally disintegrating minitablets (ODMTs)-a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm, 78:462-469
11. Lopes CM, Lobo JM, Pinto JF, Costa P. (2006). Compressed minitablets as a biphasic delivery system. Int J Pharm, 323:93-100
12. Thomson SA, Tuleu C, Wong ICK, Keady S, Pitt KG, Sutcliffe AG. (2009). Minitablets: New modality to deliver medicines to preschool-aged children. Pediatrics, 123:235-238
13. Spomer N, Klingmann V, Stoltenberg I, Lerch C, Meissner T, Breitkreutz J. (2012). Acceptance of uncoated mini-tablets in young children: Results from a prospective exploratory cross-over study. Arch Dis Child, 97:283-286
14. Lennartz P, Mielck JB. (1998). Minitabletting: Improving the compactability of paracetamol powder mixtures. Int J Pharm, 173:75-85
15. Mohamed F, Saleem R, Roberts M, Shah UU, Seton L, Ford JL.(2010). Hydrocortisone min-tablets for paediatrics. J Pharmacol Pharm, 62:1441
16. Mohamed F, Roberts M, Ford JL, Levina M, Rajabi-Siahboomi AR. The influence of HPMC concentration on release of theophylline or Hydrocortisone from extended-release mini-tablets. Drug Dev Ind Pharm, (In Press
17. Kachrimanis K, Petrides M, Malamataris S. (2005). Flow rate of some pharmaceutical diluents through die-orifices relevant to mini-tableting. Int J Pharm, 303:72-80
18. Debono M, Price JN, Ross RJ. (2009). Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab, 23:221-232
19. Howlett TA. (1997). An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf), 46:263-268
20. Greenhill LL, Findling RL, Swanson JM. (2002). A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 109:e39-.
21. Heames K, Shah U, Riby P, Blair J, Ford J, (2009). Accuracy of 2.5 mg hydrocortisone doses from quatered 10 mg tablets. Endocr Abstr, 23:OC3.1
22. Simons E. (1985). Guideline for the use of Theophylline in children with asthma. Can Med Assoc 132:1011-1012
23. Stubbs J, Haw C, Dickens G. (2008). Dose form modification - A common but potentially hazardous practice. A literature review and study of medication administration to older psychiatric inpatients. Int Psychogeriatr, 20:616-627
24. Roberts M, Vellucci D, Mostafa S, Miolane C, Marchaud D. (2012). Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets. Drug Dev Ind Pharm, 38:1068-1076
25. Jain S. (1999). Mechanical properties of powders for compaction and tableting: An overview. Pharm Sci Technol Today, 2:20-31
26. Fell JT, Newton JM. (1968). The tensile strength of lactose tablets. J Pharm Pharmacol, 20:657-659
27. Espinoza R, Hong E, Villafuerte L. (2000). Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets. Int J Pharm, 201:165-173
28. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm, 15:25-35
29. Ford JL, Mitchell K, Rowe P, Armstrong DJ, Elliott PNC, Rostron C, Hogan JE. (1991). Mathematical modelling of drug release from hydroxypropyl methylcellulose matrices: Effect of temperature. Int J Pharm, 71:95-104
30. Ford JL, Rubinstein MH, McCaul F, Hogan JE, Edgar PJ. (1987). Importance of drug type, tablet shape and added diluents on drug release kinetics from hydroxypropyl methylcellulose matrix tablets. Int J Pharm, 40:223-234
31. Moore JW, Flanner HH. (1996). Mathematical comparison of curves with an emphasis on dissolution profiles. Pharmaceut Tech, 20:64-74
32. Nokhodchi A, Ford JL, Rowe PH, Rubinstein MH. (1996). The influence of moisture content on the consolidation properties of hydroxypropylmethylcellulose K4M (HPMC 2208). J Pharm Pharmacol, 48:1116-1121
33. Huang Y, Khanvilkar KH, Moore AD, Hilliard-Lott M. (2003). Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose. Drug Dev Ind Pharm, 29:79-88
34. Tahara K, Yamamoto K, Nishihata T. (1995). Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose 2910. J Contr Release, 35:59-66
35. Yang L, Fassihi R. (1997). Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric configuration delivery system. Int J Pharm, 155:219-229
36. Fu XC, Wang GP, Liang WQ, Chow MS. (2004). Prediction of drug release from HPMC matrices: Effect of physicochemical properties of drug and polymer concentration. J Control Release, 95:209-216